The bodys homeostatic mechanisms are robust
Moderate risk (amber): prescribe GLP-1 RAs with caution (some evidence supports a benefit in these situations)
As a triple receptor agonist developed by Eli Lilly, it demonstrates promising results in human use in the management of obesity and type 2 diabetes within clinical research settings
Researchers have uncovered the molecular basis for its metabolic plasticity, pigment and metabolite regulatory networks, stress response mechanisms, and high nutraceutical value (Gupta et al., 2023
Every individual has a unique health profile
Personalized Treatment With the Precision Peptide Genetic Test The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways